Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.01.2022 17:55:44
BIOMAXIMA (BMX.WA, Warsaw)
Závěr k 28.3.2024 Změna (%) Změna (PLN) Objem obchodů (PLN)
12,20 0,70 0,26 605 656
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiBioMaxima SA
TickerBMX
Kmenové akcie:Ordinary Shares
RICBMX.WA
ISINPLBIOMX00015
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.09.2023
Akcie v oběhu k 30.09.2023 4 193 118
MěnaPLN
Kontaktní informace
Uliceul. Vetterow 5
MěstoLUBLIN
PSČ20-277
ZeměPoland
Kontatní osobaLukasz Urban
Funkce kontaktní osobyChairman of the Management Board
Telefon48 814 408 371
Fax48817442915
Kontatní telefon48 814 408 371

Business Summary: BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, BioMaxima SA revenues decreased 73% to PLN34.9M. Net income decreased 98% to PLN493K. Revenues reflect Sale of Products decrease of 74% to PLN33.5M. Net income also reflects Financial Income - Total decrease of 84% to PLN188K (income), Depreciation & Amortization increase of 18% to PLN1.8M (expense), Impairment - Goodwill - Positive decrease of 83% to PLN43K (income).
Odvětvová klasifikace
TRBC2012In-Vivo Diagnostic & Testing Substances
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSAnalytical Laboratory Instrument Manufacturing
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Analytical Laboratory Instrument Mfg
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Analytical Laboratory Instrument Manufacturing
SICDiagnostic Substances
SICAnalytical Instruments



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardRafal Jelonek-
Chairman of the Management BoardLukasz Urban4717.01.201701.12.2016
Vice Chairman of the Supervisory BoardKrzysztof Mikosz-
Vice Chairman of the Management BoardHenryk Lewczuk5717.01.201701.01.2002
Chief AccountantZaneta Homenda-01.10.201101.10.2011
Member of the Management BoardPiotr Janowski-01.01.2020
Member of the Management BoardAndrzej Mikosz-16.01.2021